PHARMACEUTICAL COMPOSITION CONTAINING NEUREGULIN ISOFORMS
A pharmaceutical composition containing a soluble Neuregulin-1 isoform representing Posttranslational Neuregulin-1 modifications.
1 . A pharmaceutical composition comprising a polypeptide which is a recombinant soluble Type I Neuregulin-1 β isoform which is an about 15 to about 35 kD N-terminal fragment of Type I Neuregulin-1 β and a pharmaceutically acceptable excipient, wherein said recombinant soluble Type I Neuregulin-1 β isoform is characterized in that it is capable of crossing the blood-brain barrier and is non-mutagenic in a mouse lymphoma thymidine kinase locus assay.
2 . The pharmaceutical composition of claim 1 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 150 to 250 amino acids of Type I Neuregulin-1 β.
3 . The pharmaceutical composition of claim 1 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 245 to 250 amino acids of Type I Neuregulin-1 β.
4 . The pharmaceutical composition of claim 1 , wherein said recombinant soluble Type I Neuregulin-1 β isoform comprises the extracellular domain of Type I Neuregulin-1 β and has a molecular mass of between 25 and 32 kD.
5 . The pharmaceutical composition of claim 1 , wherein said recombinant soluble Type I Neuregulin-1 β isoform comprises the extracellular domain of Type I Neuregulin-1 β and has a molecular mass of about 26 kD.
6 . The pharmaceutical composition of claim 1 , wherein said recombinant soluble Type I Neuregulin-1 β isoform has an isoelectric point (pl) of about 4 to about 10.
7 . The pharmaceutical composition of claim 1 , wherein said composition is formulated to be injectable.
8 . The pharmaceutical composition of claim 7 , wherein said composition is formulated to be injectable by intravenous (i.v.) injection.
9 . The pharmaceutical composition of claim 7 , wherein said composition is formulated to be injectable by subcutaneous (s.c.) injection.
10 . The pharmaceutical composition of claim 7 , wherein said composition is formulated to be injectable by intraperitoneal (i.p.) injection.
11 . The pharmaceutical composition of claim 1 , wherein said composition is formulated to be an inhalation product.
12 . The pharmaceutical composition of claim 1 , wherein said composition is formulated to be administered systemically.
13 . The pharmaceutical composition of claim 1 , further comprising a medicament for the treatment of neurological conditions.
14 . The pharmaceutical composition of claim 13 , wherein the further medicament is selected from the group consisting of acetylcholine esterase inhibitors, MAO-B-inhibitors, COMT-inhibitors, Memantine-type channel blockers, dopamine receptor agonists, serotonine receptor agonists or antogonists, catecholamine reuptake inhibitors, serotonine reuptake inhibitors.
15 . The pharmaceutical composition of claim 13 , wherein the further medicament is a medicament for the treatment of psychotic disorders.
16 . The pharmaceutical composition of claim 13 , wherein the further medicament is a medicament for the treatment of Parkinson's disease.
17 . The pharmaceutical composition of claim 13 , wherein the further medicament is a medicament for the treatment of Alzheimer's disease.
18 . The pharmaceutical composition of claim 13 , wherein the further medicament is a medicament for the treatment of Multiple Sclerosis (MS).
19 . The pharmaceutical composition of claim 13 , wherein the further medicament is a medicament for the treatment of Amyotrophic Lateral Sclerosis (ALS).
20 . The pharmaceutical composition of claim 13 , wherein the further medicament is a medicament for the treatment of epilepsy.
21 . The pharmaceutical composition of claim 13 , wherein the further medicament is a medicament for the treatment of stroke.
22 . The pharmaceutical composition of claim 13 , wherein the further medicament is a medicament for the treatment of traumatic brain injury.
23 . The pharmaceutical composition of claim 13 , wherein the further medicament is a medicament for the treatment of spinal cord injury.
24 . The pharmaceutical composition of claim 13 , wherein the further medicament is selected from clozapine, olanzapine, or gabapentin.
25 . The pharmaceutical composition of claim 13 , wherein the further medicament is a medicament for the treatment of schizophrenia, bipolar disorders or depression.